ReviewCurrent drug research reviews2026
Pharmacological Activity of Scopoletin: Deciphering the Potential of Coumarins in Cognitive Dysfunction.
Review in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated in silico docking, ADMET, and network pharmacology evaluation of Althaea officinalis L. phytocompounds targeting Park2 for the management of Parkinson's disease.Inflammopharmacology · 2026Article
- Mechanistic Interplay of Gut Microbiota and Blood-Brain Barrier Integrity in Neurodegenerative Diseases.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous therapeutic and culinary species produce scopoletin, a coumarin that is essential for treating a wide range of illnesses as a curative and chemopreventive agent. Globally, chronic illnesses are regarded as a major public health concern. Atypical regulation of various signalling pathways is the primary cause of most of these illnesses, which include cancer, as well as cardiovascular, metabolic, and neurological disorders. In Alzheimer's disease (AD), amyloid β (Aβ) peptide aggregates are deposited in the CNS, forming plaques. The investigation assessed the capacity of scopoletin to modify the disease to several AD-related factors. It activated the release of insulin in the β cell of the pancreas. Additionally, it has been noted that most currently approved treatments for these illnesses are mono-targeted and related to the development of chemoresistance, which limits their utility and prevents them from demonstrating prolonged efficacy. Conversely, the molecules originating from plants exhibit a multi-targeted nature, which has led to widespread interest in these phytochemicals due to their few adverse effects. The purpose of this review is to summarise the possible consequences of scopoletin. An outline of scopoletin pharmacology, pharmacokinetics, and toxicity is given in this review. In addition, this chemical is non-toxic and has good pharmacokinetic properties, so more research in clinical settings is necessary to develop it as a possible medication. The findings from the investigation could aid in the prevention and management of illnesses as well as the understanding of the benefits of plants containing scopoletin.
Indexed as
Identifiers
40873367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.